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Background: Few clinical trials have examined the replacement of steroids with
other immunosuppressive drugs as a primary treatment modality for minimal
change disease (MCD) in adults. We studied the efﬁcacy of tacrolimus to induce
complete remission (CR) in adults with MCD.
Methods: We enrolled 14 adults with MCD and nephrotic-range proteinuria. All
patients were treated with oral tacrolimus 0.05 mg/kg twice daily and predniso-
lone 0.5 mg/kg/day. CR was deﬁned as a urine protein to creatinine ratio ofo0.2 g
protein/g creatinine (g/g cr). The primary outcome was cumulative percentage of
CR during 16 weeks.
Results: The mean urine protein to creatinine ratio at enrollment was 10.9 g/g cr
(range: 4.2–18.1 g/g cr). The trough tacrolimus level was maintained at 5.9972.63 ng/
mL. CR was achieved by 13/14 (92.8%) patients within 8 weeks. The cumulative CR
rate was 7.7% (1/14), 64.2% (9/14), 71.3% (10/14), and 92.9% (13/14) at 1 week,
2 weeks, 4 weeks, and 8 weeks, respectively. The one remaining patient achieved CR at
20 weeks after treatment, who was followed up for a further 4 weeks. The mean time
to achieve CR in the 14 patients was 4.6475.11 (1–20) weeks. Three cases suffered
adverse events of abdominal pain, diarrhea, or new-onset diabetes mellitus.
Conclusion: Tacrolimus and low-dose prednisolone therapy induced CR rapidly
(71.3% by 4 weeks and 100% by 20 weeks) and effectively in adult patients with MCD.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Minimal change disease (MCD) is the most common cause
of childhood nephrotic syndrome and is also responsible forrean Society of Nephrology. P
ses/by-nc-nd/4.0/).
al Medicine, Seoul
i-dong 300 Bundang-gu,10–15% of the adult idiopathic nephrotic syndrome [1,2] in
western reports. In Korea, MCD is present in more than one-
third of adult cases of idiopathic nephrotic syndrome [3]. The
mainstay for MCD treatment is corticosteroids in both adults
and children. However, most of the data on the efﬁcacy of
corticosteroids in MCD come from pediatric samples [4,5]. In
2009, the Cochrane Collaboration issued the paucity of ran-
domized controlled trials for MCD treatment in adults [6].
Although the complete remission (CR) rate with cortico-ublished by Elsevier. This is an open access article under the CC BY-NC-
YC Kim et al / Tacrolimus and minimal change disease 113steroids is excellent in adults, such treatment poses several
challenges. The response rate with corticosteroids is lower in
adults than in children. Steroid dependence and resistance
also provoke concern about the undesirable effects of steroids,
such as avascular necrosis, myopathy, cataract, newly devel-
oped diabetes, and psychiatric disturbances [7]. The optimal
type and duration of therapy for initial and relapsed cases of
MCD have not been determined.
Variable corticosteroid-sparing agents such as cyclosporin,
cyclophosphamide, and mycophenolate mofetil are used to
introduce remission and reduce negative effects of corticosteroids
[8–11]. Although cyclophosphamide and cyclosporin are widely
used in MCD patients with steroid-dependent MCD [9–11],
cyclophosphamide is associated with serious side effects, such
as bonemarrow depression, gonadal failure, andmalignancy [12].
Themajor problems of cyclosporin treatment are frequent relapse
after withdrawal and the risk of renal toxicity after long-term
therapy [8]. Tacrolimus shows more potent cytokine suppression
and seems to cause less toxicity than cyclosporin as a calcineurin
inhibitor [13,14]. Although tacrolimus has been shown to be
effective in maintaining remission in pediatric patients with
steroid-dependent nephrotic syndrome, few case reports and
nonrandomized trials have been conducted to investigate the
effect of tacrolimus on CR induction in adult MCD patients [8,15].
The purpose of the present study was to evaluate the
efﬁcacy and safety of tacrolimus in the treatment of adult
patients with MCD, as a pilot study to plan a randomized
controlled trial for MCD patients with tacrolimus versus high-
dose corticosteroids. The response rate to tacrolimus was
faster than that reported in previous studies.Methods
Patients
We enrolled 14 Korean adults agedZ18 years with renal-
biopsy-proven MCD and nephrotic-range proteinuria who
were followed in a single medical center at the time of
enrollment. Nephrotic-range proteinuria was deﬁned as a
urine protein to creatinine ratio (UPCR) of43 g protein/g
creatinine (g/g cr) at two or more separate examinations
within 2 weeks, and a serum albumin levelo3 g/dL. The
exclusion criteria were systemic disease, uncontrolled hyper-
tension with systolic blood pressure4180 mmHg or diastolic
blood pressure4110 mmHg, liver function abnormalities,
pregnancy, hypersensitivity to tacrolimus or macrolides, and
previous therapy with cyclosporin or tacrolimus within
3 months. This study was not intended to reveal the factors
related to reponse rate of therapy in MCD, so, we did not
exclude MCD patients with previous chronic kidney disease.
The study was approved by the Institutional Review Board of
Seoul National University Hospital and informed consent was
obtained from all patients. This study was notiﬁed on the web
site of clinical trials (www.clinicaltrial.gov) as NCT1084980.
Deﬁnitions
MCD was diagnosed by renal biopsy. All biopsy specimens
were examined by light microscopy, immunoﬂuorescence, and
electron microscopy. The histological criteria for diagnosing
MCD included diffuse effacement of foot processes of podocytes
on electron microscopy, absence of electron-dense deposits orthickening of basement membrane, negative immunoﬂuores-
cence and absence of segmental sclerosis [7]. CR was deﬁned as
a daily UPCRo0.2 g/g cr or negative results of repeated urine
albumin dipstick test. Time to remission was the time from
initiation of therapy to the ﬁrst day on which remission was
observed. Relapse was deﬁned by UPCRZ3.0 g/g cr orZ3þ on
urine albumin dipstick in repeated measurements [7]. Steroid
dependence was deﬁned by relapse during tapering of steroids
within 6 months after CR or within 14 day of cessation of
steroids. Steroid resistance was deﬁned by persistent nephrotic
proteinuria despite high-dose steroid therapy (Z 1 mg/kg/day)
forZ12 weeks. Early CR was deﬁned as CR withino4 weeks.
Hematuria was deﬁned asZ5 red blood cells per high-power
ﬁeld. Hypertension was deﬁned as systolic blood pressur-
eZ140 mmHg, diastolic blood pressureZ90 mmHg, or taking
antihypertensive medication to control blood pressure. Diabetes
mellitus was deﬁned as fasting blood sugarZ126 mg/dL, ran-
dom blood sugarZ200 mg/dL, or taking antidiabetic medication
to control blood sugar. Acute kidney injury (AKI) was deﬁned as
a rise of serum creatinineZ0.3 mg/dL orZ50% compared to
serum creatinine in remission.
Study protocol
All patients had tacrolimus (Prografs, Astellas Pharma
Korea Inc, Seoul, Korea) 0.05 mg/kg twice daily and predni-
solone 0.5 mg/kg/day (up to 40 mg/day) until remission for 16
weeks. We performed follow-up at 1 week, 2 weeks, 4 weeks,
8 weeks, 12 weeks and 16 weeks after enrollment. At each
visit, we measured complete blood counts, liver function
tests, fasting blood glucose, total cholesterol, trough tacroli-
mus level, urinalysis including dipsticks, and UPCR. Level of
serum creatinine was reported as the value of isotope dilution
mass spectroscopy traceable creatinine (IDMS-CR). Estimated
glomerular ﬁltration rate (eGFR) was calculated using the
Modiﬁcation of Diet in Renal Disease Study (MDRD) based on
IDMS-CR [16]. We also estimated creatinine clearance from
serum and urinary creatinine levels.
Outcome variables
The cumulative rate of CR was calculated at each visit. We
reported all types of adverse events (AEs) and AEs related to
the medication.
Statistical analysis
Data were expressed as mean7standard deviation (range)
for continuous variables and as proportion for nominal data.
We compared the differences of parameters at each visit and
at baseline using paired Student t test for continuous vari-
ables and Pearson’s w2 test for nominal variables. We com-
pared the parameters using an independent Student t test
between the early and late CR groups. A p valueo0.05 was
considered statistically signiﬁcant.Results
Baseline characteristics
Fourteen Koreans were enrolled from May 2010 to March
2011. The mean age at enrollment was 33.8 (20–72) years and
Table 1. Baseline characteristics of patients
Findings
Male/female 10/4
Age at diagnosis (yr) 25.9715.5 (5–6 1)
Age at enrollment (yr) 33.8717.4 (20–72)






more than 3rd 7
Diabetes mellitus 0/14
Hypertension 3/14
AKI at presentationy 0/14
SBP (mmHg) 120.9714.1
(98–141)
DBP (mmHg) 74.9710.7 (57–96)
UPCRz 10.974.5 (4.2–18.4)
Hematuria 1/14
Serum creatinine (mg/dL) 0.8270.21 (0.60–1.31)
Ccr (mL/min) 116.3732.4 (42.5–158.3)
eGFR by MDRD equationy 109.2730.4 (39.9–148.7)
Serum albumin (g/dL) 2.270.5 (1.4–2.9)
Serum cholesterol (mg/dL) 3607104 (241–562)
Blood glucose (mg/dL) 81.4712.5 (60–109)
n Enrolled at the ﬁrst diagnosis
y acute kidney injury deﬁned as increase of serum creatinineZ0.3 mg/dL orZ50% than serum creatinine in remission
z g protein/g creatinine
y estimated using isotope dilution mass spectroscopy traceable creatinine measurement (mL/min/1.73m2). AKI, acute kidney injury; Ccr, creatinine
clearance; DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate; the Modiﬁcation of Diet in Renal Disease Study (MDRD), SBP,
systolic blood pressure; UPCR, urinary protein to creatinine ratio.
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from diagnosis to enrollment was 105.9754.0 (0–326) months.
Three patients had been diagnosed in their childhood at 5 years,
8 years and 9 years. Thirteen patients had relapsed and seven
had relapsed more than three times. The mean number of
relapse times of the 13 patients was 5.6975.91 (1–20) and
the mean frequency of relapses per year was 1.170.8 (0.2–3.0).
The initial treatment modality at renal biopsy in the 13 relapsed
patients was mainly high-dose prednisolone (1 mg/kg/day) and
one patient had high-dose prednisolone with cyclosporin
(200 mg/day). The ﬁrst treatment achieved CR in 12/13 patients
and one patient was treated with the addition of cyclosporin
and cyclophosphamide to steroids to achieve CR. The cumulative
rate of CR at the ﬁrst treatment in 13 patients was 7.7% (1/13) at
1 week, 15.4% (2/13) at 2 weeks, 69.2% (9/13) at 4 weeks, 84.6%
(11/13) at 8 weeks, and 100.0% (13/13) at 16 weeks after
treatment. At study enrollment, four patients were not taking
any immunosuppressive treatment, including corticosteroids;
six patients were taking prednisoloner5mg/day or deﬂaza-
cortr6 mg/day; two patients, prednisolone 7.5–10 mg/day; one
patient, prednisolone 35 mg/day, who had a relapse during
tapering of steroid; and one patient, 60 mg/day (1 mg/kg/day)
for 12 weeks, whom we considered to have steroid resistance.
Among the relapsed patients, ﬁve were deﬁned as steroid-
dependent because they relapsed during the steroid-tapering
schedule. Among six patients takingr5 mg/day prednisolone,
ﬁve had taken prednisolone for412 months (13–53 months)
after the last CR and were not considered as steroid-depen-
dent. There were no diabetic patients and three hypertensive
patients were enrolled. AKI was not identiﬁed. Mean UPCR
was 10.9 (4.2–18.4) g/g cr and mean serum albumin was 2.2(1.4–2.9) g/dL. eGFR by MDRD equation using IDMS-CR was
109.2730.4 (39.9–148.7) mL/min/1.73 m2.
Response to therapy
During 16 weeks, the mean tacrolimus trough blood level
was 5.9972.63 (0.3–12.3) ng/mL and the mean tacrolimus
dose was 0.09670.02 mg/kg/day. The mean prednisolone dose
was 31.576.5 mg/day (0.5070.06 mg/kg/day). The adherence
rates to tacrolimus and prednisolone were 96.574.4% (83.8–
100%) and 99.970.5% (98.2–100%), respectively. All patients
completed the 16-week course of therapy and 13/14 patients
(92.9%) achieved a CR. The one remaining patient showed UPCR
0.28 g/g cr at 16 weeks and achieved CR at 20 weeks after
therapy, who was followed for a further 4 weeks (Fig. 1). The
mean time to achieve CR was 4.6475.11 (1–20) weeks in 14
patients. The cumulative CR rate at each visit was 7.7% (1/14),
64.2% (9/14), 71.3% (10/14), 92.9% (13/14), and 100% at 1 week,
2 weeks, 4 weeks, 8 weeks and 20 weeks after therapy,
respectively (Fig. 2). This CR rate was higher than that pre-
viously reported in Western or Asian countries. The response
rate within 4 weeks after therapy was remarkable in this study
compared to others. We calculated the slope of UPCR changes
until CR from enrollment (Fig. 3). Patients with early CR with-
ino4 weeks after therapy showed a steep slope of UPCR
changes. The mean slope of UPCR changes in patients with CR
by 2 weeks after therapy was 1.0370.14 (–0.85 to –1.30)
log10[UPCR (g/g cr)]/week. The mean value of R
2 of the esti-
mated slope of the patients with CR withino4 weeks after
therapy was 0.93370.077 and the resulting line was very
nearly linear. With increasing time to achieve CR, the slopes of
Figure 1. UPCR pattern after therapy with tacrolimus and low-dose
prednisolone in adults with MCD. The asterisk-marked case did not
show CR at 16 weeks with UPCR 0.28 g protein/g creatinine, but did
achieve remission at 20 weeks after therapy. CR, complete remission;
MCD, minimal change disease; UPCR, urine protein to creatinine ratio.
Figure 2. Cumulative CR rate of adult MCD patients in this study
compared to other studies. The number on the ﬁgure is the reference
number of this manuscript. CR, complete remission; MCD, minimal
change disease.
Figure 3. Each line represents the estimated curve ﬁt for changes of
UPCR until remission in each patient. The zero point on the x axis is the
event period of CR. The y axis is the log value of UPCR. The A, B, C, D and E
lines represent the change of UPCR of a patient who achieved CR at 1 week,
2 weeks, 4 weeks, 8 weeks and 20 weeks after therapy, respectively. CR,
complete remission; UPCR, urine protein to creatinine ratio.
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mated line was decreased, and the mean values of R2 for the
estimated linear line were decreased.
The prednisolone dose at enrollment, relapse frequency,
and steroid dependence or resistance did not predict early CR
withino4 weeks after therapy but patients with early CR had
higher baseline GFR than those with CR byZ4 weeks after
therapy (124.3717.3 mL/min/1.73m2 vs. 82.0731.1 mL/min/
1.73m2, p¼0.034). The mean serum albumin levels were
increased, mean total cholesterol levels at 4 weeks, 8 weeks,
12 weeks and 16 weeks of treatment were decreased com-
pared to the baseline level, and the urine protein excretion
was decreased (all three changes signiﬁcant; Fig. 4).
AEs
The levels of serum creatinine and eGFR were not signiﬁcantly
changed during the follow-up period (109.2730.4 mL/min/
1.73 m2 at baseline and 106.578.1 mL/min/1.73 m2 at 16 weeksafter therapy). There was no case of new-onset hypertension,
infection, hepatotoxicity with elevation of Aspartate Aminotrans-
ferase (GOT) or Alanine Aminotransferase (GPT), anemia, or
leukopenia. One patient had severe abdominal pain with tacro-
limus. After decreasing the tacrolimus dose from 6mg/day to
4mg/day, the patient felt better and could take tacrolimus
without further problems. Diabetesmellitus developed at 8weeks
after therapy in another patient, and one patient had mild
diarrhea that resolved spontaneously. No patient needed to stop
medication.Discussion
In this pilot study, tacrolimus and prednisolone therapy
(0.5 mg/kg/day), lower dose of conventional prednisolone
dose (1 mg/kg/day), induced CR rapidly and effectively for
14 patients with MCD. The distinctive ﬁnding was that CR was
induced rapidly (71.3% of patients by 4 weeks, and comple-
tely, in 100% of patients by 20 weeks after therapy), and the
slope of the decrease of UPCR was constantly rapid in patients
with CR in 2 weeks. With comparing the cumulative CR rate in
the ﬁrst treatment, the response rate of this trial was more
rapid, especially CR rate at 2 weeks after treatment (15.4% vs
64.2%, w2 test with Yates’ correction, p¼0.028).
Among the 14 study patients, one was steroid-resistant to
prednisolone at 1 mg/kg/day for 12 weeks, and ﬁve were
considered steroid-dependent because they relapsed during
tapering of steroids within 6months after CR. Steroid dependency
is not well deﬁned but is considered to be indicated by a relapse
on tapering steroid therapy or within 2–4 weeks of discontinuing
steroids, and a need for long-termmaintenance steroids [7,8]. We
deﬁned steroid dependency as relapse within 6 months during
tapering of steroids or within 2 weeks after steroid cessation. In
our clinic, steroids are tapered for relatively longer duration
compared to other studies, and it takes46 months after CR.
Sometimes prednisolone is used for412 months at a dose
ofr5mg/day for routine care, although no concrete evidence
has been presented to prove the efﬁcacy of long-term steroid use
in routinely preventing relapse. Therefore, we did not include the
Figure 4. Changes of UPCR (a), serum albumin (b), and total cholesterol (c) in adult MCD patients. The vertical bar shows the 95% conﬁdence
interval of the mean value. n: difference of levels of parameters between that at each visit and at baseline, po0.05 by paired t test. MCD, minimal
change disease; UPCR, urine protein to creatinine ratio.
Kidney Res Clin Pract 31 (2012) 112–117116criterion of needing to maintain steroids for412 months as
steroid dependency. Five patients in this study had takenr5mg/
day prednisolone for412 months without relapse.
The overall rate of response (100% by 20 weeks after
therapy) to this therapy with tacrolimus and low-dose pre-
dnisolone was remarkable compared to previous studies,
especially the early response rate within 4 weeks (71.3%)
after therapy. Cumulative CR rates of nearly 30% by 4 weeks
and around 75% by 13 weeks have been reported by Waldman
in the United States [7], 42% by 4 weeks and 94% by 12 weeks
in Taiwan [17], and 58% by 4 weeks and 77% by 16 weeks in
Japan [18]. The CR rate in our study was similar to that in
children; 50% of whom respond within 2 weeks and almost all
within 8 weeks [19,20]. We could not deﬁnitively explain this
rapid response rate to tacrolimus and low-dose prednisolone.
One possible explanation is the long-term use of prednisolone
at a minimal dose ofr5 mg/day. Despite the lack of strong
evidence about the long-term effect of steroids at minimal
dose on the responsiveness to further therapy for relapse and
the prevention of relapse, one study has reported that the
long-term use of steroids might be helpful to prevent relapse
[21]. Among eight patients in the present study without
steroid dependency or resistance, ﬁve had been taking a
minimal prednisolone dose for412 months at study enroll-
ment. Second, there were no patients with AKI related to MCDin this study. AKI is reported in around 15% of adult MCD
patients [7] and is related to late response to therapy [18].
Actually, relatively low eGFR was related to late response in
the present study, although lower eGFR was due to aging
rather than AKI. Third, the rapid response may have been due
to the effect of tacrolimus. Although no randomized con-
trolled trials have been conducted to verify the effect of
tacrolimus on adult MCD, a few reports have been published
about the effect of tacrolimus on MCD. One case with steroid-
and cyclosporin-resistant MCD achieved a CR with high-dose
prednisolone and tacrolimus at 10 day after therapy [15]. In
a Chinese study of 12 adults with steroid-dependent MCD,
tacrolimus with 0.5 mg/kg/day prednisolone induced CR in
nearly 25% of patients by 2 weeks, 50% by 4 weeks, and 75% by
12 weeks, which was more effective than cyclophosphamide-
based therapy, [8]. As reviewed in other reports, the effect of
tacrolimus in MCD treatment might be related to its immu-
nosuppressive effect [22] and its potent inhibitory effect on
the release of cytokines [23]. The response rate in the present
study was rapid, even within 2 weeks, and the rate of decrease
of proteinuria in patients with CR within 2 weeks was almost
exactly linear. This suggests that the effect of tacrolimus in
inducing a CR was not only due to immunosuppression
because of rapid response time, but also resulted from the
nonimmune manner of stabilization of the actin skeleton in
YC Kim et al / Tacrolimus and minimal change disease 117podocytes [24]. Calcineurin inhibitor improved foot process
motility and prevented podocyte-loss-related proteinuria by
inhibiting the dephosphorylation of synaptopodin, which is
one of the initial steps needed for cathepsin-L-medicated
degradation of synaptopodin [25].
The AEs related to tacrolimus in the present study were
tolerable. One patient needed to stop medication for 2 weeks
due to severe abdominal pain but then continued taking it at
reduced dose without problems. Diabetes mellitus developed
in a 72-year-old patient at 8 weeks after therapy. No patient
needed to stop their medication.
This was a pilot open-label study and limited by its small
sample size and being performed only in a single center.
Although the analysis was based on a short-term follow-up of
only 16 weeks to reveal the CR rate in adult MCD patients, we
followed up all patients and could obtain the ﬁndings of MCD
by 45 weeks after treatment. Three of 14 (21.4%) patients had
relapsed at 31 weeks, 36 weeks and 40 weeks after treatment.
The period from CR to relapse was 23 weeks, 28 weeks and 38
weeks, respectively. The other limitation to verify the efﬁcacy
of tacrolimus would be that this study was not a comparative
study. We only compared the efﬁcacy of tacrolimus with low-
dose steroid to that of previous studies but not to the other
therapeutic group.
In summary, our results showed that tacrolimus and low-
dose prednisolone treatment induced CR rapidly and effec-
tively in Korean adults with MCD, including six cases of
steroid dependency or resistance. Our results suggest the
need for further investigation into the role of tacrolimus as
the ﬁrst-line therapy of MCD in anticipation of rapid CR with
a lower rate of AEs. They also provide a clue to explain the
mechanism of tacrolimus in terms of the correction of
podocytopathy in MCD.Conﬂict of interest
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